How much will the ADME Toxicology Testing industry be worth in the Future????
The global ADME
toxicology testing market
size is expected to generate a revenue of USD
10.25 billion by 2025, according to a new report by Grand View Research,
Inc., exhibiting a CAGR of 11.4%
during the forecast period. Factors such as increased need to check late-stage
drug failures with adoption of more appropriate toxicity testing methods by
pharmaceutical companies is expected to aid revenue generation for the market.
Multiple therapeutic regimens are being
followed across the globe in attempts to come up with a reliable treatment for
Covid-19. One line of treatment includes the use of hydroxychloroquine, while a
second treatment line focuses to use antiviral drugs used in the disease
management of HIV. Both these approaches have surged demand from advanced
antivirals and antimalarial drugs. This impacts the drug manufacturers as an off
label indication for these drug classes has to be worked upon. At the moment,
the WHO has not prescribed any of these approaches, neither they have commented
if one is better than the other. The report will account for Covid19 as a key
market contributor.
Absorption, distribution, metabolism,
and excretion (ADME) toxicology testing is used to test toxic reactions caused
by molecules in clinical trials on factors and systemic reactions such as
chemical, pharmaceutical, and genetic. These toxicology testing procedures help
in effective drug development, which limits or prevents toxic reactions to the
body when administered. Toxicity levels are decided on the results of a series
of tests conducted in near natural conditions, which represent almost real-time
reactions between the drug and host.
As of 2017, approximately 43.0% of
ADME toxicology testing areas carried out are based on cell culture tech. Cell
culture technology is adopted widely owing to advantages such as near natural
conditions and accurate results obtained at a cellular level.
To Request Sample Copy of this report, click the link:
These assays are conducted for several
types of toxic reactions or systems where toxic reactions might take place.
Some of the toxicity tests are systemic toxicity, renal toxicity,
hepatotoxicity, neurotoxicity, and other toxicities that might result in a
living tissue. Advancements in testing methods are underway and this trend is
likely to be picked up by many companies developing drug molecules. This will
speed up the drug discovery process and boost market growth.
Further key findings from the report suggest:
·
The market is driven by
increasing ratio of late-stage drug failures, resulting in loss of valuable
time and investment for drug development. Growth and increasing adoption of
OMICS technology is also expected to boost revenue generation in the coming
years
·
North America is the largest
market for ADME toxicology testing owing to presence of large number of
pharmaceutical companies competing for commercial launch of novel molecules
·
Developing regions of Asia
Pacific and Latin America are set to grow considerably as many multinational
and local players are striving to enter the market. They are also looking
improve their hold in markets that present innovation and growth opportunities
·
Some of the key players in this
market are Accelrys Inc.; Agilent Technologies, Inc.; Albany Molecular Research
Inc.; Beckman Coulter Inc.; Catalent Inc.; Charles River Laboratories
International Inc.; AbbVie; Actelion Pharmaceuticals; Amgen; Biocon; BioMarin;
Boehringer Ingelheim; Bristol-Myers Squibb; Cipla; and CymaBay Therapeutics.
The
global ADME toxicology testing market size was valued at USD 4.33 billion in
2017 and is expected to register a CAGR of 11.4% over the forecast period. A
rising number of drug molecules have been failing in the final stages of
clinical trials, resulting in loss of valuable time and investments in drug
discovery and development. This has resulted in increased investments in the
discovery of newer technologies for toxicity testing, which is set to boost the
market in the coming decade.
ADME
toxicology testing is mainly used for conducting various genetic, chemical, and
pharmacological tests that aid the drug discovery process, starting from drug
design to drug trails and other drug interactions. This process involves
control software, various devices to handle liquids, and other detectors that
help rapidly identify active compounds, genetic interactions, and other
biomolecular interactions. However, most of these techniques need skilled
expertise and software that can handle and store multiple sets of data at a
rapid pace. This could limit market growth to an extent.
ADME
toxicology testing is now done throughout drug design and development to
prevent any late-stage failure and to ensure systematic evaluation to prevent
potential loss of a molecule or investment. Most companies follow GLP and
non-GLP testing procedures to meet regulatory standards.
Regulatory
bodies are being pushed to establish tighter quality control standards to
achieve integrity and accuracy of obtained and stored data. However, lack of
efficient software to handle automated robotic arms and liquid handling systems
is likely to affect the market’s growth.
Browse Press Release
of this report:
Grand View Research has segmented the ADME
toxicology testing market by application, technology, method:
ADME Toxicology Testing Technology Outlook (Revenue,
USD Billion, 2014 - 2025)
·
Cell Culture
·
High Throughput
·
Molecular Imaging
·
OMICS Technology
ADME Toxicology Testing Application Outlook
(Revenue, USD Billion, 2014 - 2025)
·
Systemic Toxicity
·
Renal Toxicity
·
Hepatotoxicity
·
Neurotoxicity
·
Other Toxicities
ADME Toxicology Testing Method Outlook (Revenue, USD
Billion, 2014 - 2025)
·
Cellular Assay
·
Biochemical Assay
·
In-Silica
·
Ex-vivo
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Comments
Post a Comment